Crossmark

Smart spatial omics (S2-omics) optimizes region of interest selection to capture molecular heterogeneity in diverse tissues

Crossref DOI link: https://doi.org/10.1038/s41556-025-01811-w

Published Online: 2025-11-26

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yuan, Musu

Jin, Kaitian https://orcid.org/0009-0007-7843-1133
Yan, Hanying

Schroeder, Amelia

Luo, Chunyu

Yao, Sicong

Dumoulin, Bernhard

Levinsohn, Jonathan

Luo, Tianhao

Clemenceau, Jean R. https://orcid.org/0000-0002-6222-6457
Jang, Inyeop

Kim, Minji

Liu, Yunhe

Deng, Minghua

Furth, Emma E.

Wilson, Parker https://orcid.org/0000-0001-8647-9662
Nayak, Anupma

Lubo, Idania

Solis Soto, Luisa Maren https://orcid.org/0000-0002-1253-630X
Wang, Linghua https://orcid.org/0000-0001-9380-0266
Park, Jeong Hwan

Susztak, Katalin https://orcid.org/0000-0002-1005-3726
Hwang, Tae Hyun

Li, Mingyao https://orcid.org/0000-0001-8180-0621
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG013185)

U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (R01LM014592)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL171595)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA294518)

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (U19NS135582)
License Information

Text and Data Mining valid from 2025-11-26

Version of Record valid from 2025-11-26
More Information

Article History

Received: 8 May 2025

Accepted: 15 October 2025

First Online: 26 November 2025

Change Date: 9 April 2026

Change Type: Update

Change Details: In the version of this article initially published, the name of Schmidt Sciences was presented incorrectly in the Acknowledgements section and is now amended in the HTML and PDF versions of the article.

Competing interests

: M.L. receives research funding from Biogen unrelated to the current paper. M.L. is a co-founder of OmicPath AI. T.H.H. is a co-founder of Kure.ai therapeutics, and has received consulting fees from IQVIA; these affiliations and financial compensations are unrelated to the current paper. L.W. serves as a member of the Scientific Advisory Board for SELLAS Life Sciences and receives compensation outside the scope of this submitted work. The other authors declare no competing interests.

Document is current

Any future updates will be listed below